FDA Grants Priority Review for Pembrolizumab in Treatment of Hodgkin Lymphoma

Share this content:
The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.
The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.

The U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) that is seeking approval for pembrolizumab (Keytruda) for the treatment of patients with refractory classical Hodgkin lymphoma or those who had relapsed after 3 or more prior lines of treatment.1

The application will seek approval for the drug at a 200 mg fixed dosage delivered intravenously every 3 weeks, with a target action date by the FDA of March 15, 2017. This is the first time the drug, which is manufactured by Merck, has sought regulatory approval for a hematologic malignancy.

The decision is based on trials evaluating responses of patients with refractory classical Hodgkin lymphoma or patients who had relapsed after 3 or more prior lines of therapy.

The FDA previously granted Breakthrough Therapy Designation to pembrolizumab for the same indication in April 2016.

RELATED: Watson: A Glorified Search Engine?

In a release, Merck has stated that it is “conducting broad immune-oncology research assessing the role of monotherapy and combination regimens” for pembrolizumab in the treatment of hematologic malignancies. A clinical development program of pembrolizumab includes about 200 trials that look at the application of the drug in the treatment of a variety of cancer types.

Reference

  1. FDA grants priority review to supplemental biologics license application (sBLA) for Merck's KEYTRUDA (pembrolizumab) in relapsed or refractory classical Hodgkin lymphoma. Merck website. http://www.mercknewsroom.com/news-release/oncology-newsroom/fda-grants-priority-review-supplemental-biologics-license-application. Updated December 1, 2016. Accessed December 1, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters